IL17A and inflammatory bowel disease: Furthermore, vidofludimus, an oral immunomodulatory agent that inhibits the expression of IL17A, IL17F, and IFN-γ has shown clinical benefit in an open-label uncontrolled entrance study of patients with IBD conducted at 13 study centers in Germany, Bulgaria and Romania [34].